Mycophenolatmofetil Biomo (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolatmofetil Biomo, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat autoimmune kidney disease such as lupus nephritis in adult patients under specialist supervision and careful monitoring.

GNH USA supplies Mycophenolatmofetil Biomo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide, ensuring reliable logistics, regulatory support, timely delivery to all regions and adherence to local import requirements.

Mycophenolate Mofetil is used in immunosuppressive regimens to control immune‑mediated rejection and autoimmunity.

- Organ transplant rejection prevention: reduces the incidence of acute and chronic graft rejection. - Lupus nephritis: improves renal function and slows disease progression in systemic lupus erythematosus. - Other autoimmune disorders (e.g., vasculitis): suppresses abnormal immune activity to achieve disease control.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea - Diarrhea - Vomiting - Headache

Serious or Rare Side Effects: - Leukopenia or neutropenia - Severe opportunistic infections (e.g., Pneumocystis jirovecii pneumonia) - Hepatic dysfunction (elevated transaminases, hepatitis)

When prescribing Mycophenolate Mofetil, clinicians should observe several safety measures. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: dose may need adjustment in impaired kidneys. - Avoid in pregnancy: teratogenic risk; contraindicated. - Use effective contraception: due to Category X classification. - Vaccination: avoid live vaccines during therapy. - Store at below 25°C: keep in the original pack, protect from moisture.

Mycophenolate Mofetil has notable drug interactions that require attention.

Major Interactions (Avoid): - Azathioprine: additive bone marrow suppression. - Live vaccines: increased risk of infection. - Ritonavir/Protease inhibitors: markedly increase mycophenolate exposure.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption. - CYP3A4 inhibitors (e.g., ketoconazole): increase plasma levels. - CYP3A4 inducers (e.g., rifampin): decrease plasma levels.